Anti-IGF-1R Antibody Formulation pH Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for thyroid-associated ophthalmopathy (TAO) are inadequate due to the lack of targeted treatments for its underlying autoimmune mechanisms, and existing antibody formulations face challenges in maintaining stability and efficacy, particularly at high concentrations.
Innovation Solution
A stable formulation of anti-insulin-like growth factor 1 receptor (IGF-1R) antibodies is developed, optimized for intravenous and subcutaneous administration, with a specific pH range of 4.8-6.5 that ensures conformational and colloidal stability, allowing for high concentration and long-term stability, comprising specific heavy and light chain variable regions and stabilizing agents like sucrose and methionine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If antibodies are formulated at high concentrations for therapeutic administration, then treatment efficacy is improved, but viscosity increases and stability becomes difficult to maintain
Solution Approach 1:
The patent applies parameter changes by optimizing the pH of the formulation to a specific range (4.8-6.5) to maintain antibody stability at high concentrations. This pH optimization prevents aggregation and degradation, allowing the formulation to achieve both high antibody concentration (25-250 mg/ml) and maintained stability simultaneously.
2Quantity of substance
If antibodies are formulated at high concentrations, then treatment efficacy is improved, but viscosity increases affecting administrability
Solution Approach 1:
The patent utilizes parameter changes by adjusting the formulation pH to 4.8-6.5, which optimizes the charge state and conformational stability of the antibody. This reduces intermolecular interactions that cause viscosity, enabling high concentration formulations (25-250 mg/ml) to maintain acceptable viscosity levels for intravenous and subcutaneous administration.
3Ease of manufacture
If a universal formulation approach is used for different antibodies, then manufacturing complexity is reduced, but stability and efficacy cannot be optimized for each specific antibody
Solution Approach 1:
The patent establishes a universal formulation platform with pH 4.8-6.5 that can be applied across different anti-IGF-1R antibodies. This multi-functional approach allows the same pH optimization strategy to maintain stability and efficacy for various antibody variants, simplifying manufacturing while ensuring consistent product quality through the identified pH range.
Data Source
AI summary
Provided herein are pharmaceutical compositions of anti-IGF-1R antibodies and uses thereof.